Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)
Phase 3 trial of tirzepatide for obesity showing mean weight loss of 22.5% at 72 weeks at the highest dose.
Video claim watch
Mounjaro (tirzepatide): The newest diabetes and obesity medication
Medical doctor explainer on tirzepatide mechanism and clinical context.
Christopher McGowan, MD channel10:00 runtime315K views when checked
Connected research
Compounds discussed
Source check
Primary and peer-reviewed records
Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2)
Head-to-head trial showing tirzepatide superior to semaglutide for A1C reduction in Type 2 diabetes.
SURMOUNT-1: Tirzepatide for Obesity: ClinicalTrials.gov
ClinicalTrials.gov registry for the SURMOUNT-1 Phase 3 trial of tirzepatide for obesity, sponsored by Eli Lilly.
SURMOUNT-4: Extended Treatment with Tirzepatide: ClinicalTrials.gov
ClinicalTrials.gov registry for SURMOUNT-4, evaluating tirzepatide for extended obesity treatment.
FDA Approves Mounjaro (Tirzepatide) for Type 2 Diabetes
FDA approval of Mounjaro (tirzepatide) injection for Type 2 diabetes, NDA 215866.
FDA Approves Zepbound (Tirzepatide) for Chronic Weight Management
FDA approval of Zepbound (tirzepatide) injection for chronic weight management, NDA 217806.